Loading market dashboard
ORIC Pharmaceuticals, Inc.
ORICHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2026 (the “Grant Date”), ORIC granted a total of 216,000 non-qualified stock options and 35,000 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2026.
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC's website here.
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
LOS ANGELES--(BUSINESS WIRE)---- $ORIC--ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). The investigation focuses on ORIC's executive officers and whether investor losses may be recovered under federal securities laws.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2026 (the “Grant Date”), ORIC granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026.
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) shares gapped down prior to trading on Wednesday after Wedbush lowered their price target on the stock from $20.00 to $17.00. The stock had previously closed at $12.67, but opened at $10.25. Wedbush currently has an outperform rating on the stock. Oric Pharmaceuticals shares last traded at
Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026
Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, have been accepted for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. All regular abstracts are available for viewing via AACR's online itinerary planner located here.
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have issued a buy recommendation
Wall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc.
From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
